Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 7, 2024; 30(9): 1073-1095
Published online Mar 7, 2024. doi: 10.3748/wjg.v30.i9.1073
From liver to hormones: The endocrine consequences of cirrhosis
Juan Eduardo Quiroz-Aldave, Elman Rolando Gamarra-Osorio, María del Carmen Durand-Vásquez, Luciana del Pilar Rafael-Robles, Jhean Gabriel Gonzáles-Yovera, María Alejandra Quispe-Flores, Luis Alberto Concepción-Urteaga, Alejandro Román-González, José Paz-Ibarra, Marcio José Concepción-Zavaleta
Juan Eduardo Quiroz-Aldave, María del Carmen Durand-Vásquez, Non-communicable Diseases, Endocrinology Research Line, Hospital de Apoyo Chepén, Chepén 13871, Peru
Elman Rolando Gamarra-Osorio, Department of Endocrinology, Hospital Víctor Lazarte Echegaray, Trujillo 13006, Peru
Luciana del Pilar Rafael-Robles, Department of Endocrinology, Clínica Javier Prado, Lima 15046, Peru
Jhean Gabriel Gonzáles-Yovera, Department of Gastroenterology, Hospital Nacional Guillermo Almenara Irigoyén, Lima 15018, Peru
María Alejandra Quispe-Flores, Department of Endocrinology, Hospital de Emergencias Grau, Lima 15001, Peru
Luis Alberto Concepción-Urteaga, Internal Medicine, Hospital Regional Docente de Trujillo, Trujillo 13011, Peru
Alejandro Román-González, Department of Endocrinology, Hospital Universitario de San Vicente Fundación, Medellin 050010, Colombia
Alejandro Román-González, Internal Medicine, Universidad de Antioquia, Medellín 050010, Colombia
José Paz-Ibarra, School of Medicine, Universidad Nacional Mayor de San Marcos, Lima 15081, Peru
José Paz-Ibarra, Department of Endocrinology, Hospital Nacional Edgardo Rebagliati Martins, Lima 15072, Peru
Marcio José Concepción-Zavaleta, Carrera de Medicina Humana, Universidad Científica del Sur, Lima 15067, Peru
Author contributions: Quiroz Aldave JE contributed to conceptualization, methodology, investigation, writing-original draft, and project administration; Gamarra-Osorio ER contributed to investigation, writing-review & editing, and project administration; Durand-Vásquez MDC contributed to investigation and writing-original draft; Rafael-Robles LDP contributed to investigation and writing-original draft; Gonzáles-Yovera JG contributed to investigation and writing-review & editing; Quispe-Flores MA contributed to investigation and writing-original draft; Concepción-Urteaga LA contributed to investigation and writing-review & editing; Román-González A contributed to investigation and writing-review & editing; Paz-Ibarra J contributed to investigation and writing-review & editing; Concepción-Zavaleta MJ contributed to conceptualization, methodology, writing-review & editing, and project administration.
Conflict-of-interest statement: The authors declare no competing financial interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Marcio José Concepción-Zavaleta, MD, Medical Assistant, Professor, Research Associate, Researcher, Carrera de Medicina Humana, Universidad Científica del Sur, 19 Panamericana Sur Km, Villa El Salvador, Lima 15067, Peru. mconcepcion@cientifica.edu.pe
Received: November 4, 2023
Peer-review started: November 4, 2023
First decision: December 27, 2023
Revised: January 2, 2024
Accepted: February 6, 2024
Article in press: February 6, 2024
Published online: March 7, 2024
Abstract

Hepatocrinology explores the intricate relationship between liver function and the endocrine system. Chronic liver diseases such as liver cirrhosis can cause endocrine disorders due to toxin accumulation and protein synthesis disruption. Despite its importance, assessing endocrine issues in cirrhotic patients is frequently neglected. This article provides a comprehensive review of the epidemiology, pathophysiology, diagnosis, and treatment of endocrine disturbances in liver cirrhosis. The review was conducted using the PubMed/Medline, EMBASE, and Scielo databases, encompassing 172 articles. Liver cirrhosis is associated with endocrine disturbances, including diabetes, hypoglycemia, sarcopenia, thyroid dysfunction, hypogonadotropic hypogonadism, bone disease, adrenal insufficiency, growth hormone dysfunction, and secondary hyperaldosteronism. The optimal tools for diagnosing diabetes and detecting hypoglycemia are the oral glucose tolerance test and continuous glucose monitoring system, respectively. Sarcopenia can be assessed through imaging and functional tests, while other endocrine disorders are evaluated using hormonal assays and imaging studies. Treatment options include metformin, glucagon-like peptide-1 analogs, sodium-glucose co-transporter-2 inhibitors, and insulin, which are effective and safe for diabetes control. Established standards are followed for managing hypoglycemia, and hormone replacement therapy is often necessary for other endocrine dysfunctions. Liver transplantation can address some of these problems.

Keywords: Diabetes mellitus, Hypoglycemia, Thyroid diseases, Hypogonadism, Metabolic bone diseases, Liver cirrhosis

Core Tip: This review explores hepatocrinology, the interplay between liver function and the endocrine system, focusing on endocrine disorders in liver cirrhosis. Cirrhosis triggers endocrine disorders like diabetes, hypoglycemia, sarcopenia, hepatic bone disease, secondary hyperaldosteronism, and thyroid, adrenal and growth hormone dysfunction. Diagnosis includes biochemical and hormonal assays and imaging studies. Treatment involves drugs like metformin, insulin, and hormone replacement therapies, while liver transplantation can alleviate certain conditions. Timely recognition and intervention are crucial for reducing associated morbidity and mortality in cirrhotic patients.